Sparkle Clean Tech Licenses Oil & Gas Water Treatment Technologies from Siemens Energy, Inc.
20.1.2025 12:03:00 CET | Business Wire | Press release
This License expands Sparkle's portfolio for sustainable, integrated water solutions that support oil and gas exploration and production and support customers' waste and efficiency goals.
Sparkle Clean Tech, a global provider of process technologies and value-driven energy solutions for upstream Oil and Gas customers, is pleased to announce that it has reached an agreement with Siemens Energy to license Intellectual Property from their upstream oil and gas related water solutions technology portfolio. The license includes technologies for primary, secondary and tertiary oily water treatment, such as Corrugated Plates, Hydrocyclones, Flotation Units, Walnut Shell filters, as well as regenerable membrane-based treatment technologies. This license includes intellectual property such as patents, copyrights and trade secrets. The technologies effectively address the water and wastewater needs of the oil and gas industry.
Sparkle Clean Tech will license Siemens Energy's Monosep™ Nutshell Filtration; Perfomedia™ adsorption technology; Veirsep™ and Spinsep™ Flotation with Brise DGF Pumps or Eductors; FoldedFlo™ DAF; Liquid/Liquid Hydro cyclones with TL1.05™ Liners; and Corrugated Plate separators, along with the associated intellectual property.
The integration of these technologies will expand Sparkle Clean Tech's portfolio of sustainable and integrated offerings into the treatment of water and wastewater produced in Oil & Gas exploration and production facilities.
Mike Foster, Director of Sparkle Clean Tech, stated, "Water and wastewater management in Oil & Gas exploration and production is critical for our customers who are looking for answers to improve efficiency, make their operations more sustainable, and comply with environmental regulations and standards. This license adds to our growing integrated technology portfolio and provides yet another sustainable solution for our customers."
Sumeet Mehra, CEO Sparkle Clean Tech, stated further "We are thrilled to announce the licence of Siemens Energy's oil and gas water and wastewater treatment technologies. This strategic move reinforces our commitment to providing comprehensive and sustainable solutions to our customers in the oil and gas industry. The addition of these cutting-edge technologies to our portfolio not only expands our capabilities but also strengthens our position as a leader in integrated water solutions. We are confident that these licenses will play a significant role in supporting our customers' waste and efficiency goals while contributing to the preservation of our environment."
The licensed portfolio of technologies focuses on the treatment of oil & gas wastewater from production wells, while the Brise & Perfomedia process offers an efficient wastewater treatment solution designed to remove pollutants from produced wastewater. Both processes offer significant advancements in waste management within the oil and gas industry.
Sparkle Clean Tech is committed to driving innovation and sustainability within the oil and gas sector. By licensing Siemens Energy's upstream water treatment technologies, Sparkle Clean Tech aims to offer comprehensive solutions that support customers' waste and efficiency goals, while also contributing to environmental preservation.
About Sparkle Clean Tech:
Sparkle Clean Tech is a global provider of process technologies and value-driven energy solutions for upstream Oil and Gas customers. With a focus on sustainability and innovation, Sparkle Clean Tech aims to optimize operations and support customers' environmental goals while driving efficiency and profitability.
Sparkle Clean Tech’s other solutions include treatment technologies for water and wastewater management. Utilizing specialized Ultrafiltration, Reverse Osmosis, Desalination, and High Purity Water technologies, Sparkle addresses the needs of diverse industries including Lithium, Microelectronics, Mining among others. With a global customer footprint, Sparkle has executed several projects in the Americas, Europe, Asia, and the Middle East.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250120193068/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom